title: Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A.
abstract: The influence of chemical stability on the antimetastatic ruthenium(III) compound imidazolium trans-imidazoletetrachlorodimethylsulphoxideruthenium(III) (NAMI-A) in aqueous solution was studied both in vitro and in vivo. The loss of dimethyl-sulphoxide (DMSO) ligand from the compound was tested by using a NAMI-A solution acidified with HCl at pH 3.0 and aged for 0, 4, 8 and 24 h prior to intraperitoneal (i.p.) injection into CBA mice bearing advanced MCa mammary carcinoma. The activity of NAMI-A on lung metastases showed no change even after the loss of DMSO ligand from up to 50% of the molecules. The reduction of NAMI-A did not modify the number of KB cells blocked in the S+G2M phases, independent of whether the reduction occurred outside the cells or after loading the cells with the compound prior to treatment with the reductants (ascorbic acid, glutathione or cysteine). In vivo, the complete reduction of NAMI-A with equivalent amounts of ascorbic acid, glutathione or cysteine prior to administration to mice bearing advanced MCa mammary carcinoma was more active than NAMI-A alone. The data show that NAMI-A, although undergoing a series of chemical modifications, maintains its antimetastatic activity in a broad range of experimental conditions.
authors.affiliation: Callerio Foundation-Onlus, via A. Fleming 22-31, 34127-, Trieste, Italy. g.sava@callerio.org
authors.forename: G
authors.initials: G
authors.lastname: Sava
authors.forename: A
authors.initials: A
authors.lastname: Bergamo
authors.forename: S
authors.initials: S
authors.lastname: Zorzet
authors.forename: B
authors.initials: B
authors.lastname: Gava
authors.forename: C
authors.initials: C
authors.lastname: Casarsa
authors.forename: M
authors.initials: M
authors.lastname: Cocchietto
authors.forename: A
authors.initials: A
authors.lastname: Furlani
authors.forename: V
authors.initials: V
authors.lastname: Scarcia
authors.forename: B
authors.initials: B
authors.lastname: Serli
authors.forename: E
authors.initials: E
authors.lastname: Iengo
authors.forename: E
authors.initials: E
authors.lastname: Alessio
authors.forename: G
authors.initials: G
authors.lastname: Mestroni
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002455:Cell Division; D004121:Dimethyl Sulfoxide / Q000031:analogs & derivatives* / Q000737:chemistry* / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use; D005260:Female; D008175:Lung Neoplasms / Q000556:secondary; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008808:Mice, Inbred CBA; D009368:Neoplasm Transplantation; D009942:Organometallic Compounds / Q000737:chemistry* / Q000493:pharmacokinetics / Q000627:therapeutic use; D016196:S Phase; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D009942:Organometallic Compounds; C075498:dimethylsulfoxideimidazoletetrachlororuthenate(III); D004121:Dimethyl Sulfoxide